Helicobacter pylori and other pathogenic bacteria (H. pylori)

Helicobacter pylori is a Gram-negative, spiral-shaped bacterium that colonizes the human gastric mucosa, affecting approximately half of the global population. It is the primary etiological agent for chronic gastritis and peptic ulcer disease, and is classified as a Group 1 carcinogen due to its strong association with gastric adenocarcinoma and MALT lymphoma (NIH, 2023). The bacterium employs specialized virulence factors, such as urease, to survive the acidic environment of the stomach and induce host inflammatory responses (StatPearls, 2023). Therapeutic strategies generally involve combination regimens of antibiotics and acid-suppressing agents to achieve eradication (Mayo Clinic, 2024). The inclusion of other pathogenic bacteria encompasses a diverse array of microorganisms that cause human disease through various mechanisms of infection and immune evasion, requiring a broad spectrum of antimicrobial interventions (WHO, 2024). These pathogens often target essential bacterial processes such as cell wall synthesis, protein translation, and DNA replication to inhibit growth or induce cell death (PubMed, 2022). Understanding the specific molecular targets within these organisms is crucial for developing effective treatments and overcoming the global challenge of antimicrobial resistance.

Other names

H. pyloriGastric pathogensPathogenic microorganismsBacterial pathogens

Antibiotics target various bacterial processes including cell wall synthesis (beta-lactams), protein synthesis (macrolides, tetracyclines), and DNA replication (fluoroquinolones); proton pump inhibitors or potassium-competitive acid blockers are co-administered to increase gastric pH, which enhances antibiotic stability and efficacy against H. pylori.